Bank of New York Mellon
IMPL

Bank of New York Mellon’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Bank of New York Mellon’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-35,301
Closed -$15.2K – 4415
2023
Q3 		$15.2K Hold
35,301
– – ﹤0.01% 4271
2023
Q2 		$44.8K Hold
35,301
– – ﹤0.01% 4194
2023
Q1 		$49.4K Hold
35,301
– – ﹤0.01% 4200
2022
Q4 		$132K Hold
35,301
– – ﹤0.01% 4076
2022
Q3 		$172K Buy
35,301
+271
+0.8% +$2.08K ﹤0.01% 4069
2022
Q2 		$327K Sell
35,030
-13,107
-27% -$95.8K ﹤0.01% 3831
2022
Q1 		$306K Sell
48,137
-1,361
-3% -$10.3K ﹤0.01% 4001
2021
Q4 		$427K Buy
49,498
+15,078
+44% +$151K ﹤0.01% 3896
2021
Q3 		$419K Buy
+34,420
New +$500K ﹤0.01% 3904

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Bank of New York Mellon's IMPL Position: Q4 2023 in Review

Bank of New York Mellon sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 35,301 shares — an estimated $15.2K sold.

Bank of New York Mellon first reported a position in IMPL in Q3 2021 and held it in 9 quarters. The position peaked at $427K in Q4 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • Bank of New York Mellon reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 35,301 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $15.2K.
  • Bank of New York Mellon first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 9 quarters.
  • Bank of New York Mellon's Impel Pharmaceuticals Inc. Common Stock position peaked at $427K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.